Don’t let the high cost of brand specialty oncology therapy stand between you and the treatment you need. We help eligible patients access Erivedge (vismodegib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Erivedge Prescription Assistance Program is a manufacturer-sponsored initiative that provides Erivedge at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for advanced basal cell carcinoma patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, dermatology/oncology coordination, pregnancy-prevention documentation (Erivedge causes severe birth defects), specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your treatment, not paperwork.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$14,500.00 | Save ~$14,430/mo |
| CVS Pharmacy | ~$15,000.00 | Save ~$14,930/mo |
| Walmart | ~$13,800.00 | Save ~$13,730/mo |
| Costco | ~$13,500.00 | Save ~$13,430/mo |
| Specialty Pharmacy | ~$13,500.00 | Save ~$13,430/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Erivedge at no medication cost if approved. But the process involves detailed applications, dermatology/oncology coordination, pregnancy-prevention documentation, specialty pharmacy logistics, and ongoing renewal management. Our $69.95/month service covers full advocacy.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Erivedge:
We manage all paperwork, refills, and annual renewals
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Erivedge assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Erivedge (vismodegib) is an oral targeted oncology medicine — the first-in-class Hedgehog pathway inhibitor — used to treat advanced basal cell carcinoma that cannot be removed by surgery or treated with radiation, or that has metastasized. It is taken once daily as a 150 mg capsule.
How Erivedge Works:
Basal cell carcinoma is primarily driven by the abnormal activation of the Hedgehog signaling pathway, which causes skin cells to multiply uncontrollably. Erivedge works by selectively binding to and inhibiting Smoothened (SMO), a critical protein within that pathway. By blocking this signal, the medication interrupts the growth of the cancer, leading to tumor shrinkage and slowing the progression of the disease.
Form and use:
Erivedge is a 150 mg capsule taken by mouth once daily, and it can be consumed with or without food. It is important to swallow the capsules whole without crushing, chewing, or opening them. Treatment generally continues until the disease progresses or side effects become unacceptable, though medical teams may pause or adjust the dose to manage tolerability.
Generic availability:
As of 2026, there is no FDA-approved generic version of Erivedge available in the United States. Other options for advanced basal cell carcinoma include Sonidegib (Odomzo), another Hedgehog pathway inhibitor, or cemiplimab (Libtayo) for those eligible for PD-1 therapy. The choice of treatment depends on a patient’s medical history, prior therapies, and individual tolerability.
Warnings:
Erivedge carries a boxed warning for severe birth defects and embryo-fetal death, necessitating strict pregnancy prevention for both male and female patients. Significant side effects can include muscle spasms, hair loss, severe taste changes (dysgeusia), and weight loss. Because the drug is highly teratogenic, effective contraception must be maintained for several months to years after the final dose.
The retail price commonly runs $13,000–$15,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Erivedge at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Erivedge is taken as one 150 mg capsule by mouth once daily, with or without food. Capsules should be swallowed whole — do not open, crush, or chew them. Take it at roughly the same time each day. Treatment continues until disease progression or unacceptable toxicity.
Erivedge causes severe birth defects and embryo-fetal death. Strict pregnancy prevention is required for both female and male patients. Female patients of childbearing potential must use effective contraception during therapy and for at least 24 months after the last dose. Male patients must use condoms during therapy and for 3 months after — including with vasectomy. The medication is excreted in semen.
Yes. Sonidegib (Odomzo) is another Hedgehog pathway inhibitor approved for locally advanced basal cell carcinoma. Cemiplimab (Libtayo) is a PD-1 checkpoint inhibitor approved for patients whose advanced basal cell carcinoma has progressed on or who are intolerant to Hedgehog pathway inhibitors. Surgery and radiation remain options for many patients. Whether any of these is a better clinical fit depends on disease extent, prior treatments, and tolerability.
Yes. Medicare Part D beneficiaries can typically qualify for Erivedge Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
If your initial application is denied, we explore alternatives — the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation or HealthWell Foundation, or asking your dermatology/oncology team whether sonidegib (Odomzo) or cemiplimab (Libtayo) on a different cost path would be appropriate. If we cannot find a path, you will not be charged our service fee.
If you are struggling with the high cost of Erivedge, our team may be able to help you access assistance programs designed to make brand specialty advanced basal cell carcinoma therapy affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.